GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 392 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 392 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total transaction of $25,554.48. Following the transaction, the chief financial officer directly owned 34,942 shares in the company, valued at approximately $2,277,868.98. The trade was a 1.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total value of $438,220.80.
• On Wednesday, March 4th, Kevin Feeley sold 6,187 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total value of $486,360.07.

GeneDx Stock Performance

Shares of WGS opened at $65.38 on Friday. The firm’s 50 day moving average is $71.45 and its 200-day moving average is $107.37. The stock has a market capitalization of $1.91 billion, a P/E ratio of -87.17 and a beta of 2.06. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.34. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. The company had revenue of $120.99 million for the quarter, compared to analysts’ expectations of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. Equities research analysts anticipate that GeneDx Holdings Corp. will post 0.75 EPS for the current fiscal year.

Institutional Trading of GeneDx

A number of institutional investors and hedge funds have recently modified their holdings of the company. Arizona State Retirement System increased its position in GeneDx by 2.1% during the fourth quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock worth $728,000 after acquiring an additional 113 shares during the period. Cerity Partners LLC increased its position in GeneDx by 6.0% during the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock worth $329,000 after acquiring an additional 142 shares during the period. Main Management ETF Advisors LLC increased its position in GeneDx by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after acquiring an additional 160 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in GeneDx by 5.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after acquiring an additional 181 shares during the period. Finally, Jones Financial Companies Lllp increased its position in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

WGS has been the subject of several research reports. Zacks Research cut shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. BTIG Research decreased their price target on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. Canaccord Genuity Group set a $100.00 price target on shares of GeneDx and gave the stock a “buy” rating in a report on Monday, April 20th. Finally, Piper Sandler restated an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $134.17.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.